United States Drug Patent 10,835,542: Omadacycline CABP Claims, Exclusivity and Patent Landscape

U.S. Patent No. 10,835,542 protects specific methods of treating community-acquired bacterial pneumonia (CABP) with omadacycline, chemically identified as 9-[(2,2-dimethyl-propylamino)-methyl]-minocycline. The patent is centered on dosing schedules rather than the basic chemical compound. Its independent claims cover four regimen architectures: an intravenous loading regimen, an intravenous-to-oral step-down regimen, an oral twice-daily loading regimen, and a once-daily oral regimen.

The patent has high commercial relevance for Nuzyra because the FDA-approved CABP label uses an intravenous-to-oral regimen and an oral-only regimen that substantially overlap the claimed schedules.[1] The principal competitive threat is an ANDA or 505(b)(2) product asserting non-infringement, invalidity, or a carve-out from patented CABP use. Biosimilar risk does not apply because omadacycline is a small-molecule antibiotic.

What drug does U.S. Patent 10,835,542 protect?

The patent protects methods using omadacycline or an acceptable salt to treat CABP in humans. It does not, based on the supplied claims, broadly claim:

The omadacycline molecule itself;
Every use of omadacycline;
Every dose of omadacycline;
Every formulation of Nuzyra;
Manufacturing of omadacycline;
Treatment of infections other than CABP.

The protected subject matter is a therapeutic method requiring a defined sequence, dose, route, interval, and, in several claims, treatment duration.

The compound is marketed by Paratek Pharmaceuticals as Nuzyra. FDA approved Nuzyra in October 2018 for adults with CABP and acute bacterial skin and skin-structure infections.[1] The CABP approval was based principally on the OASIS-1 intravenous-to-oral study and the OPTIC oral-only study.[2,3]

What are the independent claims in Patent 10,835,542?

Independent claim	Core regimen	Principal scope
Claim 1	Three 100 mg IV doses 12 hours apart, followed optionally by daily 100 mg IV doses and optionally by 300 mg oral doses	Broad IV loading and optional continuation framework
Claim 21	Three 100 mg IV doses 12 hours apart, followed by one or more 300 mg oral doses	IV-to-oral step-down treatment
Claim 24	Three oral doses of 300-450 mg 12 hours apart, followed optionally by daily 300-600 mg oral doses	Oral loading regimen
Claim 39	One or two once-daily oral doses of 450-600 mg, followed by daily 300-600 mg oral doses	Once-daily oral loading and continuation regimen

Claims 1, 21, 24 and 39 are the principal infringement anchors. The dependent claims add clinical population, pathogens, administration details, treatment duration, fasting requirements, safety results and efficacy endpoints.

How does Claim 1 define the IV CABP regimen?

Claim 1 requires:

Three intravenous doses of approximately 100 mg;
Twelve-hour spacing between those initial doses;
Optional additional 100 mg IV doses at 24-hour intervals;
Optional transition to a 300 mg oral dose 12-24 hours after the preceding IV dose;
Optional additional 300 mg oral doses at 24-hour intervals.

The claim is broader than the standard full IV-to-oral course because the later IV and oral steps are expressly optional. A treatment involving only the three-dose IV loading sequence can potentially fall within claim 1 if all other claim elements are met.

The phrase "about 100 mg" creates a numerical-range issue. Courts generally construe "about" in light of the specification, prosecution history and technical context. A competing product using 100 mg per dose presents a direct literal-infringement risk. Doses materially above or below 100 mg would create a claim-construction and equivalence dispute rather than automatically avoiding the claim.

Which claims cover IV-to-oral step-down therapy?

Claims 21-23 provide the clearest IV-to-oral coverage.

Claim 21 requires:

Three 100 mg IV doses administered 12 hours apart;
One or more 300 mg oral doses after the IV phase;
Twenty-four-hour spacing between oral doses.

Claim 22 narrows the IV continuation phase to one additional 100 mg IV dose. Claim 23 requires completion within 7-14 days.

This claim group is commercially important because the FDA label permits an initial IV regimen followed by oral therapy. The FDA-approved CABP dosing schedule is:

200 mg IV over 60 minutes or 100 mg IV over 30 minutes on day 1, followed by 100 mg IV every 24 hours; or
300 mg orally twice on day 1, followed by 300 mg orally once daily.[1]

The supplied claims specify three 100 mg IV doses 12 hours apart, while the current label expresses the IV loading dose in a different format. That difference may affect literal infringement under a particular label or clinical protocol. A regimen can still face risk under the doctrine of equivalents, depending on the prosecution history and the scope of amendments made during examination.

What oral omadacycline regimens are protected?

Claims 24-30 cover an oral loading regimen involving three doses administered 12 hours apart. The loading doses may be 300 mg, 450 mg, or combinations within the stated ranges. Follow-on doses are administered every 24 hours and may range from 300 mg to 600 mg.

Claims 39-43 cover a separate once-daily loading architecture:

One or two oral loading doses of 450-600 mg;
Twenty-four-hour spacing where two loading doses are used;
Follow-on doses of 300-600 mg every 24 hours.

Claim 42 specifically covers two once-daily 450 mg doses followed by one or more 300 mg daily doses. Claim 41 covers 450 mg or 600 mg loading doses followed by 300 mg daily doses.

The oral claims are important because they reach outpatient or early-discharge treatment that avoids prolonged IV administration. They also overlap conceptually with the oral Nuzyra dosing strategy approved for CABP.[1]

What pathogens and patient populations are covered?

Claim 7 identifies CABP caused by a broad set of organisms, including:

Methicillin-resistant Staphylococcus aureus;
Streptococcus pneumoniae, including penicillin-resistant strains;
Haemophilus influenzae;
Moraxella catarrhalis;
Klebsiella pneumoniae;
Legionella pneumophila;
Chlamydophila pneumoniae;
Mycoplasma pneumoniae;
Chlamydophila psittaci;
Coxiella burnetii;
Escherichia coli.

Claim 8 limits the patient to a human. Claims 17 and 33 narrow the population to PORT Risk Class III or IV patients, generally representing moderate-to-high-risk hospitalized CABP populations.

These limitations can create non-infringement opportunities where a product label excludes CABP or where the label does not encourage treatment of the claimed disease. They do not necessarily eliminate risk from physician or hospital use if the labeled indication remains CABP.

What administration details are protected?

Intravenous infusion

Claim 10 requires each IV dose to be administered continuously over approximately 30 minutes. This limitation tracks the administration instructions for a 100 mg IV dose in the Nuzyra label.[1]

A product using a substantially different infusion duration may have an argument against literal infringement of claim 10. That change would not necessarily avoid claims 1, 21 or other claims that do not include the 30-minute limitation.

Oral tablets

Claim 9 requires each 300 mg oral dose to be administered as two 150 mg tablets. This claim is narrower than the underlying 300 mg dose limitation. A competing product supplied as a capsule, powder, suspension or different tablet strength may avoid claim 9 while remaining exposed to broader oral regimen claims.

Food restrictions

Claims 14 and 31 require fasting conditions:

At least six hours of overnight fasting before oral dosing;
No food for two hours after dosing;
No dairy products for four hours after dosing.

These limitations are relevant to product-label analysis. An ANDA applicant seeking a label that includes the same fasting instructions may increase its exposure to the dependent claims. A label omitting or materially changing those instructions may weaken literal infringement arguments, although the broader regimen claims remain separate barriers.

What clinical outcome limitations are included?

Claims 11-13 and 16-19 add clinical-performance or safety limitations.

Claim 11 requires clinical success within a 10% or 12.5% non-inferiority margin compared with moxifloxacin. Claim 12 requires improvement in at least two symptoms by day 3-5. Claim 13 adds improvement in at least one vital sign and no worsening of specified symptoms. Claim 16 recites clinical success rates ranging from approximately 70% to 100%, including an approximately 81% rate.

These claims may be harder to enforce prospectively against a product based only on its label because the clinical outcome may depend on patient characteristics and post-treatment observations. They remain relevant where clinical-trial data or actual use establishes the claimed outcomes.

Claims 18 and 19 address tolerability and microbiome-related outcomes. Claims 34-38 contain similar GI and C. difficile limitations for the oral regimen. Claims requiring a negative outcome, such as no increased C. difficile risk or no substantial microbiome disruption, may face issues involving proof, claim construction, enablement and indefiniteness.

When does Nuzyra lose regulatory exclusivity?

Exclusivity or protection	Date or status
FDA approval of Nuzyra	October 2, 2018
New chemical entity exclusivity	October 2, 2023
Pediatric exclusivity	No publicly established six-month pediatric extension should be assumed without a current FDA listing
Patent 10,835,542	Issued November 17, 2020
CABP regimen patent term	Expected to extend into the mid-2030s, subject to terminal disclaimers, patent-term adjustment and FDA patent-term extension
Generic pathway	ANDA under section 505(j), or 505(b)(2) for a different clinical or formulation strategy

The 10,835,542 patent issued after Nuzyra approval and therefore extends beyond the five-year NCE exclusivity period. The precise terminal date depends on the patent family's earliest effective nonprovisional filing date, any terminal disclaimer and patent-term adjustment. A definitive expiry calculation requires the USPTO Patent Center term data and the current FDA Orange Book entry.

What is the Orange Book status of Patent 10,835,542?

Patent 10,835,542 is a method-of-use patent associated with the approved CABP use of omadacycline. Orange Book listing analysis should distinguish three questions:

Whether the patent is listed for Nuzyra;
Which use code the FDA assigned;
Whether the approved label contains the claimed regimen.

A listed method patent can support a Paragraph IV certification if an ANDA applicant believes the patent is invalid, unenforceable or not infringed. It can also support a section viii statement if the applicant removes the patented CABP use from its proposed labeling. Section viii is difficult where CABP is the principal or only approved indication.

The FDA Orange Book remains the controlling source for current listing and delisting status. Patent ownership and Orange Book listing are separate issues. Paratek may own, license or enforce rights through related entities, while the Orange Book may identify a different patent holder or authorized party.[4]

Which companies are challenging Nuzyra exclusivity?

The relevant challengers are generic drug manufacturers pursuing an ANDA or 505(b)(2) application for omadacycline. Publicly available information does not establish a broad, commercially launched generic competitor to Nuzyra based solely on the supplied patent.

The principal challenge mechanisms are:

Paragraph IV certification against listed patents;
Section viii carve-out of CABP or another patented indication;
Paragraph III certification accepting patent expiry;
A 505(b)(2) application using a different dosage form, regimen or indication;
Declaratory judgment or district-court litigation concerning patent scope.

A generic tablet or capsule duplicating the 300 mg oral regimen faces the greatest risk under claims 24 and 39. An IV product using 100 mg dosing faces risk under claims 1 and 21. A product labeled only for acute bacterial skin and skin-structure infections could reduce CABP method-patent exposure but would still require analysis of other Orange Book patents and potential induced-infringement theories.

What patent litigation affects omadacycline?

The supplied record does not identify a final judgment, settlement or active district-court proceeding specifically adjudicating U.S. Patent 10,835,542. The patent issued in 2020, and any Paragraph IV litigation would depend on the date of an ANDA notice and the patents listed at that time.

A Paragraph IV notice generally triggers a 45-day period for the patent owner to file suit. Timely litigation can impose a 30-month FDA approval stay under the Hatch-Waxman Act, subject to statutory exceptions and court rulings.[5] A settlement may include a licensed entry date, restrictions on authorized generic competition, covenants not to sue, or other commercial terms. No settlement terms should be attributed to this patent without a filed agreement, court docket, FTC review or company disclosure.

How strong is the patent estate for Nuzyra?

Strengths

The patent has several commercial strengths:

It claims the CABP indication approved by FDA;
It covers both IV-to-oral and oral-only treatment architectures;
It includes the commercially relevant 300 mg oral maintenance dose;
It covers 100 mg IV dosing;
It reaches treatment durations of 7-14 days;
It includes dependent claims directed to resistant pathogens and higher-risk patients.

The claims also create multiple infringement theories. A competitor may avoid one narrow dependent claim while remaining exposed to an independent regimen claim.

Vulnerabilities

The estate has material vulnerabilities:

The compound and antibiotic class were known before the claimed regimens;
Dose intervals and loading strategies may be challenged as obvious combinations of clinical-trial data;
Several claims use "about," "optionally," "such that said subject is treated" and broad functional language;
Clinical success and microbiome limitations may be difficult to prove;
The claims overlap with disclosed clinical regimens, creating potential anticipation issues if the same schedule appeared in earlier publications;
The supplied claim set contains a drafting irregularity in claim 40, which depends on claim 27 while referring to a follow-on dosing step not expressly recited in claim 27.

The strongest enforcement position is likely against a labeled product that reproduces the approved CABP regimen. The weaker positions are claims dependent on clinical outcomes, microbiome effects or particular food restrictions.

What generic launch scenarios exist?

Launch scenario	Patent risk	Commercial implication
Full CABP label with 300 mg oral maintenance	High	Direct overlap with oral regimen claims
IV CABP label using 100 mg IV doses	High	Direct overlap with IV regimen claims
AABSSS-only label	Lower for this patent	CABP claims may be carved out, but other patents remain relevant
Different dose or interval	Moderate	Requires claim construction and equivalents analysis
505(b)(2) product with altered formulation	Moderate to high	Formulation and method patents may remain relevant
Post-expiry ANDA launch	Low for this patent	Other listed patents and regulatory exclusivity must be cleared
Authorized generic or licensee launch	Commercially controlled	May preserve branded economics through a negotiated entry

A skinny-label strategy may reduce induced-infringement exposure only if the carved-out label does not encourage the patented CABP use. Hospital practice, promotional materials and product information can affect the analysis.

How does Patent 10,835,542 compare with formulation and compound patents?

Patent category	Protected subject matter	Relevance to generic entry
Compound patent	Omadacycline chemical structure or salts	Blocks manufacture or sale of the active ingredient until expiry
Salt or crystal-form patent	Tosylate salt, solid form, polymorph or stability characteristics	Can block a particular API or dosage-form design
Formulation patent	Tablets, IV composition, excipients, dissolution or stability	Can block a commercial product even after method claims weaken
Method-of-use patent	CABP regimen, patient population or treatment outcome	Directly relevant to label and prescribing strategy
Manufacturing patent	API synthesis, purification or process controls	Raises supply-chain and alternative-process risks
Patent 10,835,542	CABP dosing sequences and treatment conditions	Primarily a regimen and label-use barrier

Claims 15 and 32 cover a tosylate salt, but they do not independently claim the salt as a composition. They require use of the tosylate salt within the claimed CABP methods. Separate compound, salt, formulation and process patents therefore require independent Orange Book and USPTO analysis.

What is the geographic coverage of the patent?

U.S. Patent 10,835,542 provides rights only in the United States. Related national-phase or continuation patents may exist in Europe, Canada, Japan, Australia and other markets, but foreign rights require separate analysis of:

Patent-family members;
Local claim amendments;
Patent-term adjustments or supplementary protection certificates;
National Orange Book equivalents;
Local litigation and settlement records;
Regulatory data exclusivity.

A U.S. ANDA strategy does not resolve foreign freedom-to-operate risk. Conversely, a foreign expiry date does not determine U.S. launch timing.

Key Takeaways

Patent 10,835,542 is a CABP method patent for omadacycline, not a basic compound patent.
Claims 1 and 21 target IV loading and IV-to-oral step-down regimens.
Claims 24 and 39 target oral loading and once-daily oral maintenance regimens.
The claims overlap materially with the FDA-approved Nuzyra CABP dosing framework.
The strongest risk is a full generic CABP label reproducing 100 mg IV and 300 mg oral dosing.
Narrow dependent claims cover fasting, tablet configuration, infusion duration, pathogens, PORT risk classes and treatment outcomes.
The patent was issued November 17, 2020 and is expected to provide protection beyond the 2023 NCE exclusivity expiration, potentially into the mid-2030s.
Current Orange Book listing, terminal disclaimers, patent-term adjustment and any Paragraph IV litigation must be checked before setting a launch date.
Biosimilar risk is not applicable; the relevant pathways are ANDA and 505(b)(2).
Formulation, compound, salt, manufacturing and additional method patents may create separate barriers after this patent expires.

FAQs About U.S. Patent 10,835,542 and Omadacycline

Does Patent 10,835,542 cover Nuzyra itself?

No. The supplied claims cover methods of treating CABP with omadacycline or a salt. They do not broadly claim the chemical compound as a composition.

Can a generic launch omadacycline for skin infections without infringing this patent?

Potentially, if its label omits CABP and does not encourage the patented use. Other Orange Book-listed patents and induced-infringement issues must still be assessed.

Does a different omadacycline dose avoid the patent?

Not automatically. A different dose may avoid literal infringement of a dose-specific claim, but broader claims, claim construction and the doctrine of equivalents remain relevant.

Is a 300 mg oral tablet specifically required?

Claim 9 requires two 150 mg tablets for each 300 mg oral dose. Claims 24 and 39 generally focus on dose and timing, so a different dosage form may still fall within broader claims.

Does the patent block all oral omadacycline treatment?

No. It targets specified oral loading and maintenance schedules for CABP. Oral treatment for another disease or a materially different regimen requires separate analysis.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Paratek Pharms	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018		RX	Yes	Yes	10,835,542	⤷ Start Trial				TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA	⤷ Start Trial
Paratek Pharms	NUZYRA	omadacycline tosylate	TABLET;ORAL	209816-001	Oct 2, 2018		RX	Yes	Yes	10,835,542	⤷ Start Trial				TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017353588	⤷ Start Trial
Brazil	112019008897	⤷ Start Trial
Canada	3042514	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,835,542

Which drugs does patent 10,835,542 protect, and when does it expire?

Summary for Patent: 10,835,542